GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CRH Medical Corp (AMEX:CRHM) » Definitions » EBITDA per Share

CRH Medical (CRH Medical) EBITDA per Share : $0.17 (TTM As of Dec. 2020)


View and export this data going back to 2008. Start your Free Trial

What is CRH Medical EBITDA per Share?

CRH Medical's EBITDA per Share for the three months ended in Dec. 2020 was $-0.17. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2020 was $0.17.

During the past 12 months, the average EBITDA per Share Growth Rate of CRH Medical was -75.20% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -38.10% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for CRH Medical's EBITDA per Share or its related term are showing as below:

CRHM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -54.2   Med: 28.7   Max: 158.2
Current: -38.1

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of CRH Medical was 158.20% per year. The lowest was -54.20% per year. And the median was 28.70% per year.

CRHM's 3-Year EBITDA Growth Rate is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 8.1 vs CRHM: -38.10

CRH Medical's EBITDA for the three months ended in Dec. 2020 was $-12.2 Mil.

During the past 12 months, the average EBITDA Growth Rate of CRH Medical was -75.60% per year. During the past 3 years, the average EBITDA Growth Rate was -39.00% per year. During the past 5 years, the average EBITDA Growth Rate was -0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of CRH Medical was 196.90% per year. The lowest was -90.10% per year. And the median was 19.05% per year.


CRH Medical EBITDA per Share Historical Data

The historical data trend for CRH Medical's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRH Medical EBITDA per Share Chart

CRH Medical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.71 0.68 0.66 0.17

CRH Medical Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.10 0.09 0.16 -0.17

CRH Medical EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

CRH Medical's EBITDA per Share for the fiscal year that ended in Dec. 2020 is calculated as

EBITDA per Share(A: Dec. 2020 )
=EBITDA/Shares Outstanding (Diluted Average)
=12.086/71.535
=0.17

CRH Medical's EBITDA per Share for the quarter that ended in Dec. 2020 is calculated as

EBITDA per Share(Q: Dec. 2020 )
=EBITDA/Shares Outstanding (Diluted Average)
=-12.222/71.466
=-0.17

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CRH Medical  (AMEX:CRHM) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


CRH Medical EBITDA per Share Related Terms

Thank you for viewing the detailed overview of CRH Medical's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CRH Medical (CRH Medical) Business Description

Traded in Other Exchanges
N/A
Address
999 Canada Place, Suite 578, World Trade Center, Vancouver, BC, CAN, V6C 3E1
CRH Medical Corp is a healthcare products and services company. The company, through its subsidiaries, provides anesthesiology services to gastroenterologists in the United States. It also specializes in the treatment of hemorrhoids utilizing its treatment protocol and patented proprietary technology. The company's product, the CRH O'Regan System, is a single-use, disposable, hemorrhoid treatment. It distributes the CRH O'Regan System, treatment protocols, operational and marketing services directly to gastroenterologists. Geographically, the company operates in the United States and Canada, of which key revenue is derived from the United States.
Executives
Richard Bear officer: Chief Financial Officer 9062 NE 37TH PLACE, BELLEVUE WA 98004
Ian Webb director 7385 LABURNUM ST VANCOUVER A1 V6P 5N2
James Kreger officer: President 2580 ACORN AVE NE ATLANTA GA 30305
Tushar M Ramani director, officer: Chief Executive Officer 118 TALAVERA PLACE PALM BEACH GARDENS FL 33418
Brian T Griffin director
Todd Patrick director 9029 NE 36TH STREET, BELLEVUE WA 98004
David Allan Johnson director 7464 NORTH SHORE ROAD NORFOLK VA 23505
Anthony F Holler director 8855 NORTHBROOK CT BURNABY A1
Edward Wright officer: Chief Financial Officer 2992 WEST 31ST AVE VANCOUVER A1 V6L 2A4